o2h Ventures Makes an Investment in Turbine
- On February 17, 2020
- By GrowthInvest
The o2h Therapeutics and AI Fund (“The Fund”), an early stage S/EIS fund investing in biotechnology therapeutics and related AI opportunities, is pleased to announce an investment in Turbine, a simulation-based drug discovery company. Based on a decade of research, Turbine’s biologists, bioinformaticians, data scientists, and AI engineers built the Simulated Cell. This platform is comprised of a dynamic computational model of the human cell and the underlying simulation technology to find the smartest route to novel targets, biomarkers, and combination therapies. Turbine has built a platform to understand the inner mechanisms of cancer, enabling the discovery of novel protein targets, precision biomarkers, and better translation to patients. Turbine uses its proprietary Simulated Cell technology in combination with Artificial Intelligence to build a faster and deeper biological understanding of therapeutic targets or indications, untangling the complexity of cancer. From the discussion that o2h Ventures has had with large pharma, there is demand for well validated drug targets. With high quality data, AI with its large computing power can be used effectively to understand these complex drug pathways. Sunil Shah, CEO, o2h Ventures who manages The fund alongside Prashant Shah, said: “We are very excited to be able to invest in Turbine, not only have they developed a great technology platform which big pharma will be attracted to, the entrepreneurs and co-investors are some of the best in the world..” Szabolcs Nagy, CEO and Co-Founder of Turbine, said, “Even before o2h Ventures joined the syndicate they have been very supportive referring potential advisors, introductions to VC’s and providing advice on developing the business model. They make themselves available to us whenever as required. We welcome them to the team.”
GET IN TOUCH!
MAIL US
enquiries@growthinvest.comCALL US
020 7071 3945FOLLOW US ON
Throughout our site you will find links to external websites. Although we make every effort to ensure these links are accurate, up to date and relevant, we cannot take responsibility for pages maintained by external providers.
GrowthInvest is a trading name of EIS Platforms Limited. EIS Platforms Limited (FRN: 694945) is an appointed representative of Sapphire Capital Partners LLP (FRN:565716) which is authorised and regulated by the Financial Conduct Authority in the UK.
All rights reserved 2024 @ growthinvest